Pulmonary Arterial Hypertension


Pulmonary arterial hypertension (PAH) is a chronic and life-threatening disease characterised by progressive vascular remodelling that leads to increased pulmonary vascular resistance, right ventricular heart failure and death.

PAH is defined by >25 mmHg increase in pulmonary arterial blood pressure and a pulmonary capillary wedge pressure of 15 mmHg. If left untreated, PAH is fatal; it has a survival rate of just 34% after 5 years. Current therapies include stimulating the nitric oxide (NO)–soluble guanylate cyclase (sGC)–cyclic guanosine monophosphate (cGMP) axis, improving the prostacyclin pathway or inhibiting the endothelin pathway.


Assessing Pregnancy Risk in Patients with Congenital Heart Disease


25 May 2023


US Cardiology Review 2023;17:e06.

Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction


US Cardiology Review 2018;12(1):8–12.

Impact of Atrial Septal Defect on Hemodynamics


US Cardiology Review 2017;11(2):72–4.

Pharmacologic Strategies for Management of Pulmonary Arterial Hypertension


US Cardiology Review 2016;10(2):78–84